Executive Summary
The PTAB instituted an inter partes review of Inari Medical’s 11,844,921 B2 hemostasis valve patent after Imperative Care showed a reasonable likelihood of success on multiple claims. The dispute centers on the definition of “filament” and reliance on prior art Schaffer, Hartley, and Eller.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Imperative Care, Inc. vs Inari Medical, Inc. et al. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Honeywell International Inc.vsDSM IP Assets, B.V. et al.
Honeywell seeks Director review of the PTAB’s denial of institution of its IPR against DSM’s colored‑suture patent. The petitioner contends the Board erred on patentable weight, combination rewriting, obvious‑to‑try analysis, and reasonable‑expectation‑of‑success standards. The request argues that the prior art makes the claims obvious and unpatentable.
Bio-Rad Laboratories, Inc.vsCalifornia Institute of Technology et al.
Bio-Rad Laboratories successfully secured the institution of its IPR against California Institute of Technology's patent, challenging claims based on anticipation and obviousness. The Board found that Bio-Rad demonstrated a reasonable likelihood of prevailing regarding Claim 1 over Larson.
WIZ, Inc.vsOrca Security Ltd.
WIZ, Inc. successfully navigated the institution phase of an IPR against Orca Security Ltd., demonstrating a reasonable likelihood of prevailing on its obviousness claims (35 U.S.C. § 103). The Board preliminarily agreed with Wiz's claim construction arguments regarding snapshot analysis and API usage based on prior art references.
SAMSUNG ELECTRONICS CO., LTD. et al.vsOMNI MEDSCI, INC.
Samsung and co‑petitioners have filed a PGR seeking to invalidate claim 7 of Omni MedSci’s 12,193,790 patent, arguing obviousness over Lisogurski and Carlson and invoking collateral estoppel from earlier IPRs.
Meta Platforms, Inc.vsDialect, LLC
Meta Platforms' IPR against Dialect was resolved through a settlement between Dialect and Microsoft, leading the district court to grant a stay of all deadlines. The stay provides a 29‑day window to finalize the settlement and file dismissal papers.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.